Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes

Conditions

• Diabetes
• Diabetes Mellitus, Type 2

Eligibility Criteria

Sex

ALL

Age

18 Years - 80 Years

Healthy Volunteers

Not accepted

Interventions

• liraglutide — DRUG
  1.8 mg once daily for s.c. (under the skin) injection.
• exenatide — DRUG
  10 mcg twice daily for s.c. (under the skin) injection.

Study Details

This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to compare the effect on glycaemic control of liraglutide or exenatide when added to subject's ongoing OAD (oral anti-diabetic drug) treatment of either metformin, sulphonylurea or a combination of both in subjects with type 2 diabetes. Two trial periods: A 26 week randomised, followed by a 52 week extension (14 + 38 weeks) where all subjects received liraglutide + OAD after previous randomisation to either liraglutide or exenatide, both combined with OAD treatment.

Key Dates

Start date

Aug 31, 2007

Status verified

Jan 2017

Primary completion

Apr 30, 2008

Completion

Apr 30, 2009

Study Design

Enrollment

467 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Liraglutide
  Liraglutide 1.8 mg once daily + subject's own OAD treatment
• Active Comparator: Exenatide
  Exenatide 10 mcg twice daily + subject's own OAD treatment

Primary Outcome Measure

Change in Glycosylated A1c (HbA1c) at Week 26 [ Time Frame: week 0, week 26 ]

Locations (61)

Find similar trials in Birmingham, AL

Related Studies

• Personalized Environment and Genes Study
  Recruiting · National Institute of Environmental Health Sciences (NIEHS) · Chapel Hill, North Carolina
• Pancreatic Islet Transplantation Into the Anterior Chamber of the Eye
  PHASE1/PHASE2 · Recruiting · Midhat H. Abdulreda · Miami, Florida
• Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)
  Recruiting · The University of Texas Health Science Center at San Antonio · San Antonio, Texas
• Tau PET Imaging in the Northern Manhattan Study of Metabolism and Mind.
  PHASE2 · Enrolling By Invitation · Columbia University · New York, New York